In this article I refute the smoking gun scenario, discuss why some people seemingly do not have adverse events, reveal why Cipro damages the brain, why they are still on the market, and, again, reiterate just how horribly damaging the FQ’s are to mitochondria.
Tagged: Dr. Bennett
Recently, in July 2018, Dr. Bennett published a paper about Fluoroquinolone Associated Suicide to the European Journal of Internal Medicine with the assistance of the floxed community.
In an astonishing statement from the FDA, they acknowledged that since “Psychiatric Effects” will specifically be identified within the “Central Nervous System Effects” subheading, psychiatric adverse events are automatically assumed to be part of the existing Black Box warning.
Adverse events added by the FDA are some of those requested by Dr. Bennett previously.
Dr. Charles Bennett has been able to successfully publish a paper titled “Fluoroquinolone-Related Neuropsychiatric and Mitochondrial Toxicity: a collaborative investigation by scientists and members of a social network.”
It is very disturbing that an antibiotic, which is often given out for routine infections, may result in violence, anger toward others, and horribly, may result in suicide-related adverse events.
We believe that the attention given the Fluoroquinolones through the combined media stories, past rallies, citizen petitions, in addition to community members meeting directly with FDA officials, provided some of the impetus, in part, for the scrutiny of the Fluoroquinolones being prescribed for these common health conditions.
On August 24th, 2015, members from the FQ community met with staff from the FDA in a third meeting to address the various FDA failures to adequately warn the general public about the true dangers FQ’s pose to the general public, especially our children.
Dr. Linda Martin, Dr. Alan Redd, David Melvin, and John Fratti submitted an abstract for the UMDF Symposium on behalf of the FQ community. We are pleased to announce that, after being peer-reviewed by the UMDF Abstract Review Committee, their abstract was selected as a poster for the Symposium.
“The legal and Industry Guidance bars are not too high. The problem is that the FDA has failed to do its job regarding Fluoroquinolone antibiotic safety.”, Dr. Charles Bennett, PharmedOut 2015
On June 10th, 2015 representatives from the Fluoroquinolone community met with Senate Staffers at the Dirksen Senate Building in Washington, D.C. to ensure pressure is maintained on the FDA in regards to updated warnings.